Zeiss Lightsheet 7 microscope

项目摘要 这项申请是为了获得购买蔡司Light Sheet 7显微镜的资金。这台仪器将会是 由UT Health SAN的光学成像核心设施(OIF)托管、管理和维护 Antonio(UT Health SA)，由UT Health SA和梅斯癌症协会联合管理 中心。OIF支持70个由NIH资助的实验室。仅去年一年，OIF就支持了92 外部资助的研究项目，获奖总额超过5500万美元。作为一名 梅斯癌症中心的组成部分，NCI指定的癌症中心，OIF收到了一个 在最近的NIH/NCI P30拨款续签的现场访问中，被评为“杰出”评级。类型 目前无法在UT Health SA和任何其他机构获得所需的仪器 圣安东尼奥市。获得这种新的成像方式被认为是至关重要的 命令OIF继续向我们的研究界提供所需的服务，#年 特别是，对于实现快速、低毒、高分辨率、三维成像的广泛 美国国立卫生研究院资助的大量研究项目的标本范围。这台新乐器是 对建议书中列出的主要用户尤其重要，他们的竞争非常激烈， 创新研究取决于这一仪器的可用性。调查人员，包括 无论是老牌的还是新的，来自不同的研究领域，都将大大受益。新的 仪器可以真正使人们更好地了解基本的生物系统并开发 治疗多种疾病的新策略，包括癌症、脑损伤、 退行性神经疾病、牙痛、视力疾病、骨质疏松症和骨丢失，以及 消化系统疾病。这一新仪器的问世也将刺激其他调查人员 UT Health SA和附近的机构将他们的研究转移到令人兴奋和高度竞争的领域 新方向。总体而言，这笔收购无疑将对大量 NIH资助的研究涵盖了生物医学研究中的一系列广泛的学科。

Project Summary This request is for funds to purchase a Zeiss Light Sheet 7 microscope. This instrument will be housed, managed, and maintained by the Optical Imaging Core Facility (OIF) at UT Health San Antonio (UT Health SA), which is jointly managed by UT Health SA and the Mays Cancer Center. The OIF supports 70 NIH-funded laboratories. Last year alone, the OIF supported 92 externally funded research projects with a total award amount of more than $55 million. As a component of Mays Cancer Center, an NCI designated cancer center, the OIF received an “Outstanding” rating during the recent on site visit for the NIH/NCI P30 grant renewal. The type of instrument requested is currently unavailable at UT Health SA and at any other institutions in the city of San Antonio. The acquisition of this new imaging modality is considered essential in order for the OIF to continue providing the needed services to our research community, in particular, for achieving rapid, low toxicity, high-resolution, three-dimensional imaging of a broad range of specimens for a large number of NIH-funded research projects. The new instrument is particularly critical to the major users listed in the proposal, whose highly competitive and innovative research is dependent on the availability of this instrument. Investigators, including both well-established and new, from diverse research areas, will greatly benefit. The new instrument can truly lead to a better understanding basic biological systems and to develop novel therapeutic strategies in treating many diseases states, including cancer, brain injury, degenerative neurological disease, dental pain, vision disease, osteoporosis and bone loss, and digestive disease. The availability of this new instrument will also stimulate other investigators at UT Health SA and nearby institutions to move their research into exciting and highly competitive new directions. Overall, this acquisition will without a doubt, significantly impact a large number of NIH-funded investigations covering an expansive array of disciplines in biomedical research.